Plerixafor (AMD3100)

Catalog No.S8030 Synonyms: JM 3100

Plerixafor (AMD3100) Chemical Structure

Molecular Weight(MW): 502.78

Plerixafor (AMD3100) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 97 In stock
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • BLI of NSG mice engrafted with BV173, treated with no therapy (control), plerixafor: 1 mg/kg IP daily, ESKM 100 ug twice weekly, and a combination of ESKM and plerixafor. (A) Logarithmic plot of BLI of leukemia growth measured weekly. Error bars are 5-95% confidence intervals. There was a small but not significant difference between ESKM and combination treated group. (B) End of therapy (day 34) BLI.

    Blood 2014 123(21), 3296-304. Plerixafor (AMD3100) purchased from Selleck.

    Chemotaxis (Transwell invasion) assay showing the migration of BMSCs in response to CXCL12 (0–100 ng/ml) and the inhibitory effect of the CXCR4 antagonist AMD3100 (5 mg/ml, 30 min). *P < 0.05, compared with the control group (no treatment); #P < 0.05; n = 4 wells from separate cultures.

    J Clin Invest, 2015, 125(8): 3226-40. Plerixafor (AMD3100) purchased from Selleck.

  • a, ECs were seeded onto collagen gels containing CXCL12 and incubated with vehicle (DMSO) control or AMD3100 (1 μM), rapamycin (100 nM), or PP242 (600 nM) for 24 h after before fixing and imaging. Scale bar = 150 μm. b, The average number of invading cells was calculated by counting five wells per condition.

    Angiogenesis, 2016, 19(3):359-71. Plerixafor (AMD3100) purchased from Selleck.

    (A) Pictures display representative results of the change of invading cells after incubation of human FTC cell line TT2609-C02 with different concentrations of CXCR4 antagonists AMD3100 and WZ811 as well as rh-SDF1α as receptor agonist. Cells were visualized by DAPI staining. (B) Invading cells were counted in five visual fields of at least three different membranes. Differences after treatment are illustrated as fold change to control.

    J Cancer, 2018, 9(6):929-940. Plerixafor (AMD3100) purchased from Selleck.

Purity & Quality Control

Choose Selective CXCR Inhibitors

Biological Activity

Description Plerixafor (AMD3100) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.
CXCL12 [1]
(Cell-free assay)
CXCR4 [1]
(Cell-free assay)
5.7 nM 44 nM
In vitro

Plerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. [1] Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHOK1 cells M3faWmZ2dmO2aX;uJIF{e2G7 NEn2VHlFcXOybHHj[Y1mdnRib3[gX|EzPUmfU1TGNYFteGijIH\yc40hS1iFUkSg[ZhxemW|c3XkJIlvKEOKT1uxJINmdGy|LDDJR|UxRTBwOEGgcm0> NI\zTZcyPzdzNUGyPC=>
HEK293 cells MmO1SpVv[3Srb36gZZN{[Xl? MXyyJIRigXN? MlXDRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWFIxNXKnc3nzeIFvfCCKSW[xJG5NPC1|IHnu[oVkfGWmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFIh\GG7czygTWM2OD1{LkOgcm0> M2j2Z|E6PDVzM{C1
PBMC cells NWnTWlYyTnWwY4Tpc44h[XO|YYm= NWKwWWVZTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gc4Yh[2:vcH;1coQh[WejaX7zeEBJUVZvMTC4PU43KHO2cnHpckBqdiCSQl3DJINmdGy|LDDFR|UxRTNwODDuUS=> MmfsNVQ3QThzOEm=
human MT4 cells MXfGeY5kfGmxbjDhd5NigQ>? MlTtOEBl[Xm| M2DZcWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNicnXwcIlk[XSrb36gZYZ1\XJiNDDkZZl{KGK7IF3UWEBie3OjeTygSWM2OD12IH7N NVnSemloOjByNEO2N|g>
human Jurkat cells NX70OHdyTnWwY4Tpc44h[XO|YYm= MV7BcpRi\2:waYP0JIFkfGm4aYT5JIF1KEO[Q2K0JIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOGRkGtbY5lfWOnZDDj[YxtKG2rZ4LheIlwdixiSVO1NF0zPy52IH7N M4XPWFE6OTh6MEex
MT-4 cells NWPSV2F[TnWwY4Tpc44h[XO|YYm= M4O1cGVn\mWldHn2[UBkd26lZX70doF1cW:wIH;mJINwdXCxdX7kJIFo[Wmwc4SgTGlXNTFiSVnJRkB{fHKjaX6gbY4hVVRvNDDj[YxteyxiRVO1NF03PSCwTR?= NF7ZNIMyPDZ7OEG4PS=>
rat IR983F cells NGH4VFFHfW6ldHnvckBie3OjeR?= NFHERXZFcXOybHHj[Y1mdnRib3[gX|EzPUmfQ2jDUFEzKG[{b32gR3hEWjRiaX6gdoF1KEmUOUizSkBk\WyuczygTWM2OD1zMEigcm0> M1\nbFE6ODV|N{[4
CEM-SS cells NWfaUppqTnWwY4Tpc44h[XO|YYm= NHu3ZZBG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDv[kBkd22yb4Xu[EBi\2GrboP0JGhKXi1zIFzBTUB{fHKjaX6gbY4hS0WPLWPTJINmdGy|LDDFR|UxRTF{NzDuUS=> NFHkcVcyPDZ7OEG4PS=>
human HL60 cells NUXmOmJKTnWwY4Tpc44h[XO|YYm= MmG1SIl{eGyjY3Xt[Y51KG:oIGuxNlVKZVOGRkHhcJBp[SCocn;tJGNZS1J2IHnuJIh2dWGwIFjMOlAh[2WubIOsJGlEPTB;MUWuNkDPxE1? MWmxPVE5QDB5MR?=
human MOLT4 cells MXXGeY5kfGmxbjDhd5NigQ>? NIjOenMyODByIH7N NIHBXYVKdmirYnn0bY9vKG:oIF3hZkAyOkd3IHLpcoRqdmdidH:gR3hEWjRiZYjwdoV{e2WmIHnuJIh2dWGwIF3PUHQ1KGOnbHzzJIF1KDFyMECgcm0h[nliRlHDV{BidmGueYPpdy=> NYj1NWp1OTl2NUGzNFU>
human MT2 cells MlPMSpVv[3Srb36gZZN{[Xl? NVjPNFNROSC3Zz;tUC=> NE[zZmw1KGSjeYO= MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHB{NDDhcpRq\2WwIIDyc4R2[3Srb36gZZQhOSC3Zz;tUEBi\nSncjC0JIRigXNiYomgSWxKW0F? NGLRepkzOTF4OEOzOi=>
human U87 cells Mn3ESpVv[3Srb36gZZN{[Xl? MmnBNVAxOCCwTR?= NEfVWodCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFPYR3I1KGmwIHj1cYFvKFV6NzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOGRkGtbY5lfWOnZDDtc4R2dGG2aX;uJI9nKGODTWCgdJJw\HWldHnvckBifCBzMECwJI5OKGK7IGTSMWZTTVRiYYPzZZk> MmXsNVc6PTh|NES=

... Click to View More Cell Line Experimental Data

In vivo A single topical application of Plerixafor promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. [3] Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixafor injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixafor. [4]


Animal Research:[4]
+ Expand
  • Animal Models: Twelve-week-old C57BL/6 mice with segmental bone defect
  • Formulation: PBS
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (198.89 mM)
Water 3 mg/mL warmed (5.96 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 502.78


CAS No. 110078-46-1
Storage powder
in solvent
Synonyms JM 3100

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03653247 Not yet recruiting Sickle Cell Disease Bioverativ - a sanofi company|Bioverativ Therapeutics Inc. December 2018 Phase 1|Phase 2
NCT03664830 Recruiting Sickle Cell Disease City of Hope Medical Center September 19 2018 Phase 1
NCT03506802 Recruiting HLA-A*0201 Positive Cells Present|NY-ESO-1 Positive Tumor Cells Present|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) July 10 2018 Phase 1
NCT03547830 Recruiting Chronic Granulomatous Disease Federal Research Institute of Pediatric Hematology Oncology and Immunology May 29 2018 Phase 2
NCT03182426 Recruiting Diabetes Mellitus Type 1 University of Alberta|Alberta Innovates Health Solutions August 15 2017 Phase 1|Phase 2
NCT03240861 Recruiting HLA-A*0201 Positive Cells Present|Locally Advanced Malignant Neoplasm|NY-ESO-1 Positive|Unresectable Malignant Neoplasm Jonsson Comprehensive Cancer Center|California Institute for Regenerative Medicine|National Cancer Institute (NCI) July 26 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the half-life of the product (Cat S8030)?

  • Answer:

    The biological half-life for this drug is 3-5 hours:

CXCR Signaling Pathway Map

Related CXCR Products0

Tags: buy Plerixafor (AMD3100) | Plerixafor (AMD3100) ic50 | Plerixafor (AMD3100) price | Plerixafor (AMD3100) cost | Plerixafor (AMD3100) solubility dmso | Plerixafor (AMD3100) purchase | Plerixafor (AMD3100) manufacturer | Plerixafor (AMD3100) research buy | Plerixafor (AMD3100) order | Plerixafor (AMD3100) mouse | Plerixafor (AMD3100) chemical structure | Plerixafor (AMD3100) mw | Plerixafor (AMD3100) molecular weight | Plerixafor (AMD3100) datasheet | Plerixafor (AMD3100) supplier | Plerixafor (AMD3100) in vitro | Plerixafor (AMD3100) cell line | Plerixafor (AMD3100) concentration | Plerixafor (AMD3100) nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID